NCT03721653View on ClinicalTrials.gov

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

June 15, 2021

Study Completion Date

August 31, 2023

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Bevacizumab

5 mg/kg iv over 30 minutes day 1

DRUG

Irinotecan

165 mg/sqm iv over 60 minutes day 1

DRUG

Oxaliplatin

85 mg/sqm iv over 2 hours day 1

DRUG

L-Leucovorin

200 mg/sqm iv over 2 hours day 1

DRUG

5-fluorouracil

3200 mg/sqm 48 h-continuous infusion

DRUG

Atezolizumab

840 mg iv over 30 minutes (60 minutes at the first infusion) day 1

Trial Locations (1)

56126

Francesca Vannini, Pisa

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Gruppo Oncologico del Nord-Ovest

OTHER

NCT03721653 - FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter